DC
GYRE icon

Davenport & Co’s Gyre Therapeutics GYRE Stock Holding History

Davenport & Co’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,920
Closed -$244K – 1094
2021
Q3 		$244K Sell
7,920
-1,333
-14% -$43.9K ﹤0.01% 922
2021
Q2 		$301K Buy
9,253
+906
+11% +$31.1K ﹤0.01% 783
2021
Q1 		$316K Buy
8,347
+467
+6% +$21.3K ﹤0.01% 640
2020
Q4 		$373K Buy
+7,880
New +$341K ﹤0.01% 592

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Davenport & Co's GYRE Position: Q4 2021 in Review

Davenport & Co sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 7,920 shares — an estimated $244K sold.

Davenport & Co first reported a position in GYRE in Q4 2020 and held it in 4 quarters. The position peaked at $373K in Q4 2020. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

  • Davenport & Co reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Davenport & Co sold 7,920 Gyre Therapeutics shares in Q4 2021, an estimated $244K.
  • Davenport & Co first reported a position in Gyre Therapeutics in Q4 2020 and held it in 4 quarters.
  • Davenport & Co's Gyre Therapeutics position peaked at $373K in Q4 2020.
  • 51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on Davenport & Co's 13F filing for Q4 2021, filed 10 Feb 2022.